The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

  ()
Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. read more >

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

  ()
Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation. read more >

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug

  ()
Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc. read more >

Coronavirus Propels Telemedicine into the Spotlight

Contributed Opinion
  ()
McAlinden Research Partners takes a look at how telemedicine companies are positioned to profit both during and in the wake of the current pandemic, and offers a couple of options for investors. read more >

Biopharma to Accelerate Alzheimer Trial Completion

Research Report
  ()
The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report. read more >

Clinical Catalysts Impending for California-Based Biopharma

Research Report
  ()
The firm's three upcoming potential stock movers are reviewed in a ROTH Capital Partners report. read more >

iBio Shares Trade Up 40% After Announcing Development of Proprietary COVID-19 Vaccine Candidates

  ()
iBio Inc. shares traded higher after the company reported that it has filed several provisional patents for its SARS-CoV-2 Virus-Like Particle platform with the U.S. Patent and Trademark Office. read more >

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

  ()
Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. read more >

Predictive Oncology Launches AI Vaccine and Drug Platform & Acquires Technology

  ()
Shares of Predictive Oncology traded higher after the company reported that it launched a new AI vaccine and drug development platform targeting coronaviruses and acute respiratory syndromes and that it is acquiring Soluble Therapeutics assets including its HSC Technology. read more >

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

  ()
Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. read more >

U.S.-Based Biotech 'Growing into a Giant with AI'

Research Report
  ()
How Moderna uses and benefits from digitization and artificial intelligence are described in a ROTH Capital Partners report. read more >

Antibody Developer Taken Out by Gilead at 'Hefty Premium'

Research Report
  ()
The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. read more >

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

  ()
Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. read more >

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

  ()
Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. read more >

Sangamo Shares Trade 30% Higher on Q4 Earnings and Biogen Collaboration

  ()
Sangamo Therapeutics shares traded higher after the company reported Q4/19 and FY/19 earnings and advised that it signed a global collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular and neurological diseases. read more >

Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study

  ()
Shares of Moderna traded higher after the company reported that it has developed and shipped an mRNA vaccine against novel coronavirus for use in a Phase 1 testing study in the U.S. read more >

Two Stock-Moving Catalysts Expected in March for Biopharma

Research Report
  ()
These events for Axsome Therapeutics are described in an H.C. Wainwright & Co. report. read more >

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial

  ()
Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. read more >

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

  ()
Shares of Baudax Bio traded higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. read more >

FDA Approval of Biopharma's Pain Drug Expected This Year

Research Report
  ()
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. read more >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation

  ()
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. read more >
News Update

Life Sciences Firm Contracts with Philippines Distributor

News Update
  ()
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. read more >

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

  ()
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. read more >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

  ()
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. read more >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

Research Report
  ()
The events in that trio are presented in a ROTH Capital Partners report. read more >
Showing Results: 1 to 25 of 115 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"The June 2020 start-up for MAG's Juanicipio is positive." ❭
– Bhakti Pavani, Alliance Global Partners
"PVG's Brucejack continues to deliver strong free cash flows." ❭
– Andrew Mikitchook, M Partners
"The drills are still turning, and GBR has plenty of cash." ❭
– Eric Coffin, HRA Journal
"We came away from a site visit to LIO's Tuvatu very impressed." ❭
– Ryan Walker, Echelon Wealth Partners
"SEA stock should do well in the coming bull market." ❭
– Derek Macpherson, Red Cloud Securities